<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00992524</url>
  </required_header>
  <id_info>
    <org_study_id>ORALTIMI</org_study_id>
    <nct_id>NCT00992524</nct_id>
  </id_info>
  <brief_title>Oral Titrated Misoprostol for Induction of Labour</brief_title>
  <acronym>OTISMISO</acronym>
  <official_title>Oral Misoprostol Titrated Solution Versus Vaginal Misoprostol for Induction of Labour: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Materno Infantil Prof. Fernando Figueira</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Saúde Elpidio de Almeida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidade Federal do Ceara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Materno Infantil Prof. Fernando Figueira</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare effectiveness and safety of an oral titrated solution
      of misoprostol with vaginal misoprostol for induction of labour with an alive fetus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several methods for induction of labour are available. However, the most effective and with
      less frequency of adverse effects is still unknown. Vaginal misoprostol has been used
      frequently to induce labour but other routes of administrations have been proposed, such as
      oral, sublingual and, more recently, oral titrated solution. The purpose of this study is to
      compare effectiveness and safety of this oral misoprostol titrated solution with vaginal
      misoprostol administration for induction of labour with an alive fetus. A randomized
      controlled double-blind trial will be carried in three hospitals: Instituto de Medicina
      Integral Prof. Fernando Figueira, Universidade Federal do Ceará and Instituto de Saúde
      Elpídio de Almeida, from November 2009 to November 2011. A total of 400 patients must be
      enrolled. Inclusion criteria are: a) indication for labour induction; b) term pregnancy with
      alive fetus; Bishop score less than six. Exclusion criteria are: a) age less than 18 years;
      b) previous uterine scar; c) nonvertex presentation; d) non-reassuring fetal status; e) fetal
      anomalies; f) fetal growth restriction; g) genital bleeding; h) tumors, malformations and/or
      ulcers of vulva, perineum or vagina. They will be randomized to receive an oral misoprostol
      titrated solution with vaginal placebo tablet or oral placebo solution with vaginal
      misoprostol tablet. Oral solution will have misoprostol at a concentration of 2mcg/ml or
      placebo. Vaginal tablets will have 25mcg of misoprostol or placebo. Oral solution dose will
      be 20mcg/hour (misoprostol) or 10ml/hour (placebo) in the first six hours with an increase of
      20mcg/hour (10ml/hour) of misoprostol or placebo each six hours if labour does not start,
      until the maximum dose of 80mcg/hour or 40ml/hour in the first 24 hours. This maximum dose
      can be maintained for more 24 hours if needed. Vaginal misoprostol or placebo tablets will be
      administered for each six hours until the maximum dose of 200mcg or eight tablets. Primary
      outcomes will be vaginal delivery within 24 hours, hyperstimulation syndrome, cesarean
      section, severe neonatal morbidity or perinatal death, serious maternal morbidity or maternal
      death. Secondary outcomes will be need of oxytocin for augmentation of labour, number of
      misoprostol doses needed to bring on labour, interval from first dose to labour and first
      dose to delivery, failed induction, tachysystole, uterine rupture, need of labour analgesia,
      instrumental delivery, side effects, maternal death, meconium, non-reassuring fetal heart
      rate, Apgar scores less than seven at 1st and 5th minutes, admission at neonatal intensive
      care unit, neonatal encephalopaty, perinatal death and women not satisfied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaginal delivery</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hyperstimulation syndrome</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cesarean section</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe neonatal morbidity or perinatal death</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious maternal morbidity or maternal death</measure>
    <time_frame>42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need of oxytocin for augmentation of labour</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of doses needed to bring on labour</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interval from 1st dose to labour</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interval from 1st dose to delivery</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failed induction</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tachysystole</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine rupture</measure>
    <time_frame>72 houras</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of labour analgesia</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instrumental delivery</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects: nausea, vomit, diarrhea, postpartum haemorrhage</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal death</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meconium</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-reassuring fetal heart rate</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar scores less than 7 at 1st and 5th minute</measure>
    <time_frame>1st and 5th minutes after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission at neonatal intensive care unit</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perinatal or neonatal death</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal encephalopathy</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Women not satisfied with route of drug administration</measure>
    <time_frame>48 hours after delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Labor, Induced</condition>
  <arm_group>
    <arm_group_label>Oral Titrated Misoprostol Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal Misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Oral solution dose will be 20mcg/hour (misoprostol) or 10ml/hour (placebo) in the first six hours with an increase of 20mcg/hour (10ml/hour) of misoprostol or placebo each six hours if labour does not start, until the maximum dose of 80mcg/hour or 40ml/hour in the first 24 hours.</description>
    <arm_group_label>Oral Titrated Misoprostol Solution</arm_group_label>
    <other_name>Prostokos</other_name>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Vaginal tablets will have 25mcg of misoprostol or placebo.</description>
    <arm_group_label>Vaginal Misoprostol</arm_group_label>
    <other_name>Prostokos</other_name>
    <other_name>Cytotec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for labour induction

          -  Term pregnancy with alive fetus

          -  Bishop score less than six

        Exclusion Criteria:

          -  Age less than 18 years

          -  Previous uterine scar

          -  Nonvertex presentation

          -  Non-reassuring fetal status

          -  Fetal anomalies

          -  Fetal growth restriction

          -  Genital bleeding

          -  Tumors, malformations and/or ulcers of vulva, perineum or vagina
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex SR Souza, Phd student</last_name>
    <role>Study Chair</role>
    <affiliation>Professor Fernando Figueira Integral Medicine Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melania MR Amorim, Phd</last_name>
    <role>Study Director</role>
    <affiliation>Professor Fernando Figueira Integral Medicine Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aurélio AR Costa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor Fernando Figueira Integral Medicine Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Medicina Integral Professor Fernando Figueira (IMIP)</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50070-550</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2009</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Alex Sandro Rolland de Souza</name_title>
    <organization>Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)</organization>
  </responsible_party>
  <keyword>Misoprostol</keyword>
  <keyword>Labor, Obstetric</keyword>
  <keyword>Labor, Induced</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

